source
- US biotech M&A surges as Chinese licensing deals dominate 2026 marketLocust Walk reports that China now accounts for 58% of global licensing deal value in 2026, while the United States share has dropped to 26%. Despite the licensing shift, US biotech companies are…
- Crossover fundraisings may hit $4.2 billion in 2026, with 2025 rounds still leading historic totalsCrossover rounds are viewed as a bridge to public markets, with Jim Healy of Sofinnova Investments saying a large raise signals a company has reached a level of maturity and broader institutional i…